Bleeding Disorders
From the Journals
Tailored hemophilia prophylaxis could cut costs
Tailored frequency-escalated prophylaxis resulted in less use of recombinant factor VIII.
Conference Coverage
Gene therapy reduces ABR, AIR in hemophilia B
GLASGOW—New research suggests the gene therapy SPK-9001 can reduce bleeding and the need for factor IX infusions in patients with hemophilia B....
Conference Coverage
N9-GP has better PK profile than rFIXFc, team says
GLASGOW—Nonacog beta pegol (N9-GP) has a better pharmacokinetic (PK) profile than recombinant factor IX-Fc fusion protein (rFIXFc), according to...
Conference Coverage
Therapy can extend half-life of FVIII
GLASGOW—Preliminary data suggest an investigational therapy can extend the half-life of factor VIII (FVIII) in patients with severe hemophilia A...
News from the FDA/CDC
FDA approves Doptelet for liver disease patients undergoing procedures
Avatrombopag (Doptelet) is the first drug approved for thrombocytopenia in adults who have chronic liver disease and are undergoing a procedure....
Conference Coverage
Emicizumab reduces bleeding in hemophilia A
GLASGOW—Final results from the HAVEN 3 study suggest emicizumab prophylaxis can reduce bleeding in hemophilia A patients without factor VIII...
Conference Coverage
Structured PPH management cuts severe hemorrhage
AUSTIN, TEX. – The checklist-driven approach yielded reductions in other morbidity surrogates as well.
Conference Coverage
Hydroxyurea in infancy yields better SCD outcomes
PITTSBURGH – Patients with SCD started on hydroxyurea before age 1 year had better lab and clinical results than did those started a few months...
From the Journals
Adding vasopressin in distributive shock may cut AF risk
Adding vasopressin cut risk of atrial fibrillation, compared with catecholamine vasopressors alone.
Conference Coverage
NHLBI seeks to accelerate hemostasis/thrombosis research
SAN DIEGO – About half of hemostasis/thrombosis research is basic in nature.
News
Single injection could treat hemophilia B long-term
Cell therapy could produce lasting effects in hemophilia B, according to a group of researchers. They genetically modified induced pluripotent...